Skip to Content

Becton, Dickinson and Co BDX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Becton, Dickinson Delivers In-Line Q4 2021; Subdued 2022 Guidance Due to Declining COVID-19 Revenue

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We maintain our fair value estimate for narrow-moat Becton, Dickinson following the release of fourth-quarter results and fiscal 2022 guidance. We currently view Becton, Dickinson as slightly undervalued.

Read Full Analysis

Company Profile

Business Description

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Contact
1 Becton Drive
Franklin Lakes, NJ, 07417-1880
T +1 201 847-6800
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Sep 30, 2021
Fiscal Year End Sep 30, 2021
Stock Type Aggressive Growth
Employees 75,000

Related